Cited by 22Organ Transplantation Techniques and OutcomesLiver Disease and TransplantationTransplantation: Methods and Outcomes

Evaluation of recipients with significant comorbidity - patients with cardiovascular disease

Open access
Tsochatzis, Emmanuel A., Watt, Kymberly D., VanWagner, Lisa B., Verna, Elizabeth C., Berzigotti, Annalisa·2023·Journal of Hepatology

Abstract

Liver transplant(ation) (LT) is the most effective treatment for patients with decompensated liver disease. The increasing prevalence of obesity and type 2 diabetes and the growing number of patients with non-alcoholic fatty liver disease being evaluated for LT, have resulted in a greater proportion of LT candidates presenting with a higher risk of cardiovascular disease. As cardiovascular disease is a major cause of morbidity and mortality after LT, a thorough cardiovascular evaluation pre-LT is crucial. In this review, we discuss the latest evidence on the cardiovascular evaluation of LT candidates and we focus on the most prevalent conditions, namely ischaemic heart disease, atrial fibrillation and other arrhythmias, valvular heart disease, and cardiomyopathies. LT candidates undergo an electrocardiogram, a resting transthoracic echocardiography and an assessment of their cardiopulmonary functional ability as part of their standardised pre-LT work-up. Further diagnostic work-up is undertaken based on the results of the baseline evaluation and may include a coronary computed tomography angiography in patients with cardiovascular risk factors. The evaluation of potential LT candidates for cardiovascular disease requires a multidisciplinary approach, with input from anaesthetists, cardiologists, hepatologists and transplant surgeons.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2023.03.023

Cites

138 of 138 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Candidates with MASLD can be safely transplanted, if properly managed.

    “Despite the overall higher rate of risk factors in adults with MASLD, long-term graft and recipient survival after liver transplantation do not differ in many retrospective and registry analyses, 482,486,487 supporting that candidates with MASLD can be safely transplanted, if properly”

    From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [488]

    The Cardiovascular risk assessment section discusses evaluating NASH-related cirrhosis candidates before liver transplantation, and the Conclusions call for robust assessment and testing as NAFLD becomes more prevalent. This supports the need for careful management, but the paper does not report comparable long-term graft or recipient survival for MASLD recipients or establish that they can be safely transplanted as a group. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 4

  1. [60]Reddy ST, Thai NL, Oliva J, Tom KB, Dishart MK, Doyle M, Cardiohepatic risk assessment by CMR imaging in liver transplant candidates. Clin Transplant 2018; 32: e13229. 29498104
  2. [83]LiverTox Amiodarone. Clinical and research information on drug-induced liver injury. 2012. Bethesda (MD). 31643176
  3. [108]Izzy M, VanWagner LB, Lin G, Altieri M, Findlay JY, Oh JK, Redefining cirrhotic cardiomyopathy for the modern era. Hepatol 2020; 71: 334– 345. PMC7288530 31342529
  4. [114]Izzy M, Fortune BE, Serper M, Bhave N, deLemos A, Gallegos-Orozco JF, Management of cardiac diseases in liver transplant recipients: comprehensive review and multidisciplinary practice-based recommendations. Am J Transplant: official J Am Soc Transplant Am Soc Transpl Surgeons 2022; 22: 2740– 2758. PMC9522925 35359027

Cited by

Sorted by citations

Authors
Tsochatzis, E. A., Watt, K. D., VanWagner, L. B., Verna, E. C., & Berzigotti, A.
Affiliations
  • The Royal Free Hospital (GB)
  • Mayo Clinic (US)
  • The University of Texas Southwestern Medical Center (US)
  • Columbia University Irving Medical Center (US)
  • University of Bern (CH)
Corresponding author
Tsochatzis, Emmanuel A.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2023-06
Volume
78
Issue
6
Pages
1089-1104
ISSN
0168-8278 (ISSN-L)
OpenAlex
W4376870737
Cited by
22
References
138
Citations by year
2026: 4 · 2025: 7 · 2024: 9 · 2023: 2
FWCI
1.42
Type
journal article
Language
en
Open access
Locations
  • Journal of Hepatology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • BORIS (University Library Bern) (submittedVersion)
Funders
National Heart, Lung, and Blood Institute (R56HL155093)
Topics
  • Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
Keywords
liver transplantation, cardiovascular disease, transplant evaluation, ischemic heart disease, atrial fibrillation, cardiac arrhythmias, valvular heart disease, cardiomyopathy, non-alcoholic fatty liver disease, obesity, type 2 diabetes, coronary CT angiography
MeSH terms
Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Risk Factors, Comorbidity, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review